Iambic Therapeutics

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

OpenAI Strawberry Model is a cutting-edge AI initiative that represents a significant leap in AI capabilities, focusing on enhancing reasoning, problem-solving, and complex task execution. It aims to improve AI's ability to handle mathematical problems, programming tasks, and deep research, including long-term planning and action. The project showcases advancements in AI safety and aims to reduce errors in AI responses by generating high-quality synthetic data for training future models. Strawberry is designed to achieve human-like reasoning and is expected to play a crucial role in the development of OpenAI's next major model, codenamed 'Orion.'

Nucleai is an AI-driven spatial biomarker analysis tool that leverages military intelligence-grade geospatial AI methods to analyze complex cellular interactions in a patient's biopsy. The platform offers a first-of-its-kind multimodal solution by ingesting images from various modalities and delivering actionable insights to optimize biomarker scoring, predict response to therapy, and revolutionize disease diagnosis and treatment.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Shaped is an AI tool designed to provide relevant recommendations and search results to increase engagement, conversion, and revenue. It offers a configurable system that adapts in real-time, with features such as easy set-up, real-time adaptability, state-of-the-art model library, high customizability, and explainable results. Shaped is suitable for technical teams and offers white-glove support. It specializes in real-time ranking systems and supports multi-modal unstructured data understanding. The tool ensures secure infrastructure and has advantages like increased redemption rate, average order value, and diversity.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus's innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, a tool to identify and close gaps in care; LENS, a platform to find, access, and analyze multimodal real-world data; and ALGOS, algorithmic models connected to Tempus's assays to provide additional insight.

Sensae is an AI-powered biofeedback platform that uses data-driven techniques to enhance personal well-being. It integrates physiology and psychology using haptic biofeedback to help people reconnect with their inner emotions. Sensae's technology provides deep insights into the body and mind, uncovering hidden emotional patterns and revealing the complex web of human behavior and thinking. The platform offers a range of modules, including advanced bio-monitoring, stress assessment, heart rate variability assessment, and psychometric testing. Sensae's proprietary wearable device provides haptic biofeedback, creating a direct feedback loop that ensures the effectiveness of both stimuli and interventions.

fal.ai is a generative media platform designed for developers to build the next generation of creativity. It offers lightning-fast inference and access to high-quality generative media models optimized by the fal Inference Engine™. Developers can fine-tune their own models, leverage the fastest AI inference engine for diffusion models, and benefit from the expertise of Fal's head of AI research, Simo Ryu, in implementing LoRAs for diffusion models. The platform provides a world-class developer experience and cost-effective scalability, allowing users to pay only for the computing power they consume.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.

Intelligencia AI is a leading provider of AI-powered solutions for the pharmaceutical industry. Our suite of solutions helps de-risk and enhance clinical development and decision-making. We use a combination of data, AI, and machine learning to provide insights into the probability of success for drugs across multiple therapeutic areas. Our solutions are used by many of the top global pharmaceutical companies to improve their R&D productivity and make more informed decisions.

Modality.AI is an AI application that has developed an automated, clinically validated system to assess neurological and psychiatric states both in clinic and remotely. The platform utilizes conversational AI to monitor conditions accurately and consistently, allowing researchers and clinicians to review data in near real-time and monitor treatment response over time. Modality.AI collaborates with world-class AI/Machine Learning experts and leading institutions to provide a HIPAA-compliant system for assessing various indications such as ALS, Parkinson's, depression, autism, Huntington's Disease, schizophrenia, and mild cognitive impairment. The platform enables convenient monitoring at home through streaming and analysis of speech and facial responses, without the need for special software or apps. Modality.AI is accessible on various devices with a browser, webcam, and microphone, offering a new approach to efficient and cost-effective clinical trials.

Fathom5 is a company that specializes in the intersection of AI and industrial systems. They offer a range of products and services to help customers build more resilient, flexible, and efficient industrial systems. Fathom5's approach is unique in that they take a security-first approach to cyber-physical system design. This means that security is built into every stage of the development process, from ideation to engineering to testing to deployment. This approach has been proven to achieve higher system resiliency and faster regulatory compliance at a reduced cost.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover valuable insights. The platform is purpose-built for various conditions such as cancer, immune, endocrine, metabolic system, chronic diseases, aging, infectious diseases, and mental health, offering solutions for early biomarker discovery, drug repurposing, lead identification, compound optimization, trial monitoring, and response to treatment. JADBio is trusted by partners in precision health & medicine and is continuously evolving to disrupt drug discovery times and costs at all stages.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

PubCompare is a powerful AI-powered tool that helps scientists search, compare, and evaluate experimental protocols. With over 40 million protocols in its database, PubCompare is the largest repository of trusted experimental protocols. PubCompare's AI-powered search features allow users to find similar protocols, highlight critical steps, and evaluate the reproducibility of protocols based on in-protocol citations. PubCompare is available from any computer and requires no download.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Deep Genomics is a company that uses artificial intelligence (AI) to develop RNA therapies for genetic diseases. The company's AI platform is designed to identify novel targets and evaluate thousands of possibilities to identify the best therapeutic candidates. Deep Genomics is currently developing BigRNA+, which will expand the number of mechanisms and genetic variants the company can pursue.

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery blending science and technology with a focus on finding solutions for complex diseases. We empower both biopharmaceutical companies and our internal scientists to harness the full potential of data and AI to accelerate the next generation of scientific advances. We have built our AI-enabled drug discovery engine to drive a revolution in drug discovery. The Benevolent Platform™ unlocks the power of a vast biomedical data landscape to provide a multidimensional representation of human biology across all diseases. We believe this approach will improve the probability of clinical success, and help us deliver life-changing treatments to patients – because it matters.

XtalPi is a world-leading technology company driven by artificial intelligence (AI) and robotics to innovate in the fields of life sciences and new materials. Founded in 2015 at the Massachusetts Institute of Technology (MIT), the company is committed to realizing digital and intelligent innovation in the fields of life sciences and new materials. Based on cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale experimental robot clusters, the company provides innovative technologies, services, and products for global industries such as biomedicine, chemicals, new energy, and new materials.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.

Bionl is a no-code bioinformatics platform designed to streamline biomedical research for researchers and scientists. It offers a full workspace with features such as bioinformatics pipelines customization, GenAI for data analysis, AI-powered literature search, PDF analysis, and access to public datasets. Bionl aims to automate cloud, file system, data, and workflow management for efficient and precise analyses. The platform caters to Pharma and Biotech companies, academic researchers, and bioinformatics CROs, providing powerful tools for genetic analysis and speeding up research processes.

Genie TechBio is the world's first AI bioinformatician, offering an LLM-powered omics analysis software that operates entirely in natural language, eliminating the need for coding. Researchers can effortlessly analyze extensive datasets by engaging in a conversation with Genie, receiving recommendations for analysis pipelines, and obtaining results. The tool aims to accelerate biomedical research and empower scientists with newfound data analysis capabilities.

HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.

Lavo Life Sciences is an AI-accelerated crystal structure prediction application that aims to accelerate drug development processes. The platform provides solutions for de-risking pipelines, optimizing solid-state formulations, and avoiding late-stage surprises using AI technology. Lavo Life Sciences combines the expertise of chemists and engineers in AI and computational chemistry to offer innovative solutions for drug development teams.

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

CHAI AI Platform is an AI tool designed for quant traders to build and implement AI algorithms for trading. The platform combines chat functionality with AI capabilities to enhance the trading experience. Based in Palo Alto, CA, CHAI Research Corp. developed the platform to empower traders with advanced AI technology for better decision-making and performance in the financial markets.

SOMA is a Research Automation Platform that accelerates medical innovation by providing up to 100x speedup through process automation. The platform analyzes medical research articles, extracts important concepts, and identifies causal and associative relationships between them. It organizes this information into a specialized database forming a knowledge graph. Researchers can retrieve causal chains, access specific research articles, and perform tasks like concept analysis, drug repurposing, and target discovery. SOMA enhances literature review efficiency by finding relevant articles based on causal chains and keywords specified by the user. It empowers researchers to focus on their research by saving up to 95% of the time spent on pre-processing documents. The platform offers freemium access with extended functionality for 14 days and advanced features available through subscription.

Cambrian Copilot is an AI tool designed for researchers and engineers to easily stay up-to-date with the latest machine learning research. With over 240,000 ML papers available for search, the tool helps users understand complex details and automate literature reviews, simplifying the process of discovering and accessing cutting-edge research in the field of machine learning.

Mnemonic AI is an advanced Customer Intelligence AI tool that specializes in creating AI Personas and Digital Twin of the Customer. It helps organizations of all sizes better understand individuals by developing artificial intelligence solutions to tailor messages to their state of mind. The tool is fully automated, data-driven, and offers psychographics insights, integrations, and case studies to enhance customer centricity and marketing strategies.

functime is a time-series machine learning tool designed to perform forecasting at scale. It provides a comprehensive set of functions and resources to assist users in analyzing and evaluating time-series data. With features like scoring, ranking, and plotting functions, functime aims to simplify the process of forecasting and make it accessible to users of all levels of expertise. The tool also offers an API reference for developers looking to integrate time-series forecasting capabilities into their applications.

Kolank is an AI tool that provides a unified API for accessing a wide range of Language Model Models (LLMs) and providers. It offers features such as model comparison based on price, latency, output, context, and throughput, OpenAI compatible API integration, transparency in tracking API calls and token expenditure, cost reduction by paying for performance, load balancing with fallbacks, and easy integration with preferred LLMs using Python, Javascript, and Curl.

Promptmakr is a platform that facilitates the buying and selling of AI prompts. It serves as a marketplace where users can find and purchase prompts for various AI applications. The platform aims to streamline the process of acquiring prompts, making it easier for developers and AI enthusiasts to access high-quality content to enhance their projects.

StockGPT is an AI-powered financial research assistant that provides knowledge of earnings releases, financial reports, and fundamental information for S&P 500 and Nasdaq companies. It offers features like AI search, customizable filters, up-to-date data, industry research, and more to help users analyze companies and markets effectively.

Unlearn.ai is an AI-powered digital twins solution provider that optimizes clinical trials. Their TwinRCTs enable confident and quick clinical trials in various medical fields such as neuroscience, immunology, and metabolic diseases. By creating digital twins of patients, Unlearn.ai enhances the power and efficiency of clinical trials, attracting study participants and making confident decisions from early to late-stage studies.

Altera is an applied research lab focused on building digital human beings with fundamental human qualities. Led by Dr. Robert Yang, the team consists of computational neuroscientists, physics olympiads, and engineers from prestigious institutions. Their mission is to create digital beings that enhance human-to-human interactions, offering empathy, fun, friendship, and productivity at an unprecedented scale. Leveraging a state-of-the-art Composite Architecture inspired by the brain, Altera aims to develop agents with empathy, memory, and social norms. Starting with products in games, Altera plans to expand into multi-agent simulations and physical embodiment of digital intelligence, aspiring to become the most consequential technology company in the world.